Résumé
CMF regimen contains Cyclophosphamide. Methotrexate and 5-fluorouracil which was developed in "Istituto Nazionale Tumori in Milan and has found to be effective in both pie-menopausal and post-menopausal breast cancer patients. Since it contains some hepatotoxic drug components so we tried to evaluate the cumulative hepatotoxicity of this combination, both in acute and chronic phases. In case of acute toxicity the regimen is found to be safe. However in case of chronic toxicity, it is found to produce mild effects in patients receiving less than three cycles and moderate effects in patients receiving more than three cycles. This represents that benefit versus risk should be assessed before giving CMF regimen to the patients, especially when other drugs like analgesics or antidepressants are prescribed with it